Baird raised the firm’s price target on Cardinal Health (CAH) to $203 from $197 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target raised to $185 from $183 at Wells Fargo
- Cardinal Health’s Growth Potential: Buy Rating Reaffirmed Amid Strong Pharma Performance and Strategic Focus
- Cardinal Health Reports Strong Q4 and FY 2025 Results
- Cardinal Health: Strategic Acquisitions and Raised Guidance Justify Buy Rating
- Cardinal Health’s Strong Performance and Strategic Initiatives Justify Buy Rating